A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

详细信息    查看全文

• 作者：B. Venugopal ; A. Awada ; T. R. J. Evans ; S. Dueland…
• 关键词：CP ; 4126 ; CO ; 101 ; Gemcitabine ; Pharmacokinetics ; Pancreatic cancer ; Nucleoside transporter ; hENT1
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：76
• 期：4
• 页码：785-792
• 全文大小：421 KB
• 参考文献：1.Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-413PubMed
  2.Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-30PubMed
  3.Damaraju VL, Damaraju S, Young JD et al (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-536CrossRef PubMed
  4.Mori R, Ishikawa T, Ichikawa Y et al (2007) Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 17:1201-205PubMed
  5.Mackey JR, Mani RS, Selner M et al (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349-357PubMed
  6.Mackey JR, Yao SY, Smith KM et al (1999) Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91:1876-881CrossRef PubMed
  7.Bergman AM, Adema AD, Balzarini J et al (2011) Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest N Drugs 29:456-66CrossRef
  8.Venugopal B, Evans TRJ (2011) Gemcitabine elaidate. Drugs Fut 36:427CrossRef
  9.Stuurman FE, Lolkema MP, Huitema AD et al. (2013) A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. J Clin Pharmacol 53:878-83CrossRef PubMed
  10.Therasse P, Arbuck SG, Eisenhauer EA, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-16CrossRef PubMed
  11.Gupta N, Ahmed I, Steinberg H et al (2002) Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 25:96-00CrossRef PubMed
  12.Maniwa K, Tanaka E, Inoue T et al (2003) An autopsy case of acute pulmonary toxicity associated with gemcitabine. Intern Med 42:1022-025CrossRef PubMed
  13.Peters GJ, Clavel M, Noordhuis P et al. (2007) Clinical phase I and pharmacology study of gemcitabine (2-2-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother 19:212-21CrossRef PubMed
  14.Abbruzzese J, Grunewald R, Weeks E et al. (1991) A phase I clinical plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-98PubMed
  15.Farrell JJ, Elsaleh H, Garcia M et al (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187-95CrossRef PubMed
  16.Giovannetti E, Del Tacca M, Mey V et al (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66:3928-935CrossRef PubMed
  17.Poplin E, Wasan H, Rolfe L et al (2013) Randomized, multicenter, Phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 31:4453-461CrossRef PubMed
  18.Li D, Pant S, Ryan DP et al (2014) A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 14:398-02PubMed Central CrossRef PubMed
  
• 作者单位：B. Venugopal (1) (2)
  A. Awada (3)
  T. R. J. Evans (1) (2)
  S. Dueland (4)
  A. Hendlisz (3)
  W. Rasch (5)
  K. Hernes (5)
  S. Hagen (5)
  S. Aamdal (4)
  
  1. Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK
  2. Institute of Cancer Sciences, University of Glasgow, Switchback Road, Glasgow, G61 1BD, UK
  3. Institut Jules Bordet, Université Libre de Bruxelles, 121, Boulevard de Waterloo, 1000, Brussels, Belgium
  4. Department of Oncology, Oslo University Hospital, Oslo, Norway
  5. Clavis Pharma ASA, Parkveien 53 B, 0256, Oslo, Norway
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Background CP-4126 (gemcitabine elaidate, previously CO-101) is a lipid–drug conjugate of gemcitabine designed to circumvent human equilibrative nucleoside transporter1-related resistance to gemcitabine. The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of CP-4126, and to describe its pharmacokinetic profile.